Objectives: To evaluate clinical characteristics and outcomes of patients treated with thoracic endovascular aortic repair (TEVAR) at our institution. Material and methods: Prospectively registered patients undergoing TEVAR at Odense University Hospital were consecutively included in the study between June 1999 and January 2015. Results: 189 patients underwent TEVAR in the observation period. Mean follow-up time was 6 years (SD AE 4). Sixty-three percent (N ¼ 119) were men; mean age was 65 years (SD AE 15). Based upon underlying disease, patients were divided into four groups: 1: Aneurysmal disease (N ¼ 89), 2: aortic type B dissection (N ¼ 64), 3: traumatic lesions (N ¼ 33) and others (N ¼ 3). Sixty percent (N ¼ 114) were performed as emergency procedures. Technical success, defined as no immediate endoleak type 1 and no on-table death, was achieved in 96% (N ¼ 181) of the cases. Thirty-day mortality was 12% (N ¼ 23) whereof the majority (96%) were procedures performed acutely. Long-term mortality was 28% (N ¼ 52), highest in the aneurysmal group accounting for 62% of the total deaths. Seven perioperative events were registered, including paraplegia (N ¼ 2) and ischemia of the left arm (N ¼ 5). Conclusion: In this single-center study, we evaluated characteristics and long-term outcome of patients treated with TEVAR based on 4 different indications. A high degree of technical success as well as a low number of perioperative complications was achieved.
cells (RBC) when haemoglobin levels drop below 5 mmol/L, while in the vascular surgical patient, local guidelines often use a higher trigger for RBC transfusion. Low haemoglobin levels decrease blood O 2 transport capacity that could provoke tissue ischaemia, however, administration of blood products may have side effects. We are in the process of planning a feasibility-trial to examine the effect of RBC transfusion on tissue oxygenation. Methods: In a single-center, open-label trial design, fifty vascular surgical patients (> 40 years of age) awaiting open surgical repair of the abdominal aorta or infra-inguinal arterial bypass surgery in general anaesthesia will undergo a web-based randomisation to one of two groups: peri-operative RBC transfusion when haemoglobin decreases to < 5 mmol/L or RBC transfusion triggered by a haemoglobin < 6 mmol/L. Administration of fluid follows an individualised goal-directed strategy by optimising cardiac stroke volume. Near-infrared spectroscopy (NIRS) determines regional oxygenation with optodes placed on the forehead and on the upper arm. The trial is powered to show a difference between the two groups for post-operative haemoglobin of 1.0 mmol/L (primary outcome), for the number of RBC transfusions by two units, and for NIRS-determined tissue oxygenation by 6%. On the first and second postoperative day, the occurrence of tissue ischaemia is suggested by an increase in troponine-I to above 45 ng/L. Renal failure is indicated by a creatinine-increment > 26.5 mmol/L (or 1.5 times the preoperative value) or a drop in urine production to below 0.5 ml/kg/h over six hours. A follow-up at thirty days after surgery is also planned. The first patient was included July 30th 2015. The trial is approved by the Ethics Committee of Region Sjaelland (SJ-426) and registered in ClinicalTrials.gov (NCT02465125). Results: Analysis of data will be initiated when fifty patients are included. An abstract is planned for the Danish Society for Vascular Surgery annual meeting 2016. A manuscript will be submitted shortly thereafter. Conclusion: This trial is expected to deliver information on whether RBC transfusion triggered by a haemoglobin < 6 mmol/L compared to a haemoglobin < 5 mmol/L is more favourable in terms of peripheral tissue oxygenation, use of blood products and levels of haemoglobin. A multicenter trial for evaluation of postoperative mortality is warranted.
